Minimal Residual Disease in Mantle Cell Lymphoma
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference68 articles.
1. Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
2. The addition of rituximab to CHOP improves failure-free and overall survival of mantle-cell lymphoma patients—a pooled trials analysis of the German Low-Grade Lymphoma Study Group (GLSG) [abstract];Hoster;Blood,2014
3. Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group;Geisler;Blood,2008
4. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)
5. Nordic Lymphoma Group. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant;Andersen;Eur J Haematol,2003
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Minimal residual disease detection in lymphoma: methods, procedures and clinical significance;Frontiers in Immunology;2024-08-12
2. Defining an Optimized Workflow for Enriching and Analyzing Residual Tumor Populations Using Intracellular Markers;The Journal of Molecular Diagnostics;2024-04
3. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2023-12
4. Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial;Journal of Clinical Oncology;2023-11-22
5. Advances in Monitoring and Prognostication for Lymphoma by Flow Cytometry;Clinics in Laboratory Medicine;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3